Background: COPD is an age-related disease. The role of cellular senescence in COPD has not been fully elucidated. This study examined the relationship between telomere length of peripheral blood leukocytes and clinical outcomes, including health status, rate of exacerbations, and risk of mortality in individuals with COPD. Methods: Using quantitative polymerase chain reaction, we measured the absolute telomere length (aTL) of DNA extracted from blood samples of 576 participants with moderate-to-severe COPD treated with either azithromycin or placebo for 12 months in the Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO) study. All participants were followed for approximately 13 months, during which time health status and exacerbations were carefully ascertained, and an additional 29 months for mortality. The rates of exacerbation and mortality were determined by dividing the aTL into two groups using the median value as the cutoff. Results: Participants with shorter telomere length had worse health status defined by higher St. George's Respiratory Questionnaire scores (β = −0.09, P =.034). In the placebo arm of the study, the rate of exacerbation (rate ratio, 1.50; 95% CI, 1.16-1.95; P =.002) and the risk of mortality (hazard ratio, 9.45; 95% CI, 2.85-31.36; P =.015) were significantly higher in the shorter telomere group than in the longer telomere group; these differences were not observed in the azithromycin arm (interaction P =.008 for exacerbation and interaction P =.017 for mortality) Conclusions: These data suggest that replicative senescence may help to predict poor outcomes in COPD. Shorter leukocyte telomere lengths may represent a clinically translatable biomarker for identifying individuals at increased risk of poor clinical outcomes in COPD.
Bibliographical noteFunding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: N. F. is a paid employee of GenomeDx Biosciences Inc. P. G. W. has served as a consultant to Astra-Zeneca, Theravance, Regeneron, Sanofi, and Genentech. M. K. H. has consulted for GSK, Boehringer Ingelheim, Astra-Zeneca, Novartis, and Sunovion and has received in kind support from Novartis and Sunovion. D. D. S. has received research funding support from Merck, AstraZeneca, and Boehringer Ingelheim and has served on advisory boards of Sanofi-Aventis, Regeneron and AstraZeneca. None declared (M. J., E. C. L., S. W. R., S. T., G. J. C., S. C. L., R. A., J. E. C., F. J. M., S. D. A., R. M. R., S. F. P. M., J. M. L.).
- quality of life